Licensing · Global (LMICs) · Announced 16 Nov 2026

Gilead Sciences → Eva Pharma

Gilead signed a royalty-free voluntary licence with Egypt's Eva Pharma to manufacture and supply investigational obeldesivir for Ebola Bundibugyo post-exposure prophylaxis across 127 mainly low- and lower-middle-income countries, pending trial data and approvals.

Parties: Gilead Sciences (United States) → Eva Pharma (Egypt)

Deal type
Licensing
Value
Royalty-free
Territory
127 countries, primarily low- and lower-middle-income, including all African countries that have reported cases in the current Ebola Bundibugyo outbreak
Therapeutic area
Infectious Disease
Asset
obeldesivir
Announced
16 Nov 2026

Our analysis

Why this matters

On 16 November 2026 Gilead Sciences announced royalty-free voluntary licensing agreements with three generic manufacturers — Eva Pharma, Dr. Reddy's Laboratories and Ferozsons Laboratories — for obeldesivir, an investigational oral antiviral being studied for post-exposure prophylaxis (PEP) of Ebola Bundibugyo virus disease (BVD). The licences cover 127 countries, primarily low- and lower-middle-income, including every African country that has reported cases in the current outbreak.

The agreements were signed before results are available from EBO-PEP, a partner-led Phase 3 randomised, placebo-controlled trial coordinated by ALIMA. Obeldesivir is not approved for any indication in any country; licensees may manufacture and supply it only if clinical data and regulatory authorisations support it. Technology-transfer discussions are underway, and Gilead says further manufacturers are under discussion.

The full analysis is free to read with a work email on this page.

Source: Gilead Sciences press release

More deals involving Gilead Sciences or Eva Pharma

Latest deals

All Global (LMICs) deals → · All licensing deals → · Browse all emerging-market pharma deals →